Here’s a move that’s sure to spark some debate among baseball fans: Pitcher José Urquidy has inked a $1.5 million, one-year deal with the Pittsburgh Pirates, marking a new chapter in his career. But here’s where it gets interesting—this agreement, confirmed by a source close to the negotiations to The Associated Press, comes with a twist. The deal is contingent on Urquidy passing a physical, which adds a layer of uncertainty to the mix. And this is the part most people miss: Urquidy’s journey to this point has been anything but straightforward.
At 30, the right-handed pitcher brings valuable depth to the Pirates’ roster, which is already anchored by NL Cy Young Award winner Paul Skenes. What makes this signing particularly intriguing is Urquidy’s flexibility—he can be optioned to the minor leagues, giving the Pirates strategic roster management options. But here’s the controversial angle: Is this a calculated risk or a gamble for the Pirates? Urquidy underwent Tommy John surgery in June 2024 while with the Houston Astros, and his return to the majors last September with the Detroit Tigers was brief, with just two relief appearances and a 7.71 ERA over 2 1/3 innings. Does this raise questions about his durability moving forward?
A six-year major league veteran, Urquidy boasts a 27-16 record with a 4.00 ERA across 70 starts and 11 relief appearances for the Astros (2019-23) and Tigers. His postseason resume is equally impressive, with a 4.08 ERA in 15 appearances, including eight starts. However, his 2024 season was cut short by a forearm strain that led to surgery, leaving fans and analysts alike wondering: Can he return to his previous form? Or will his injury history limit his impact with the Pirates?
This signing isn’t just about adding a player—it’s about potential. If Urquidy can regain his pre-injury form, he could be a steal at $1.5 million. But if his health remains a question mark, it could be a costly experiment. What do you think? Is this a smart move by the Pirates, or are they taking an unnecessary risk? Let us know in the comments—this is one deal that’s bound to keep the conversation going.
